Ras-Rasayan exports face distinct classification, labelling and heavy-metal testing requirements in the US and EU that brand owners must resolve before.
Ras-Rasayan products containing processed minerals and metals face significant regulatory scrutiny in the United States and European Union. Understanding the classification frameworks, heavy-metal testing standards and documentation requirements in both markets before committing to export production saves considerable time and cost for Ayurvedic brand owners and distributors planning cross-border supply.
Ras-Rasayan is the Ayurvedic category that most reliably contains processed metals and minerals. Formulations in this range incorporate bhasma preparations (Abhrak Bhasma, Tamra Bhasma, Loha Bhasma and others) as well as mercurial preparations such as Kajjali. These ingredients are intrinsically associated with heavy-metal content, even after the classical shodhana and marana purification cycles that are intended to reduce toxicity and convert the metal into a stable form.
Regulatory agencies in the United States and European Union do not recognise classical Ayurvedic purification as a process that removes heavy-metal risk in the way Indian pharmacopoeial standards do. Their frameworks measure finished product metal content against limits designed for the general population and for products that do not rely on traditional processing rationales. This fundamental difference in regulatory philosophy is the starting point for every export compliance strategy involving Ras-Rasayan products, and exporters who approach the US or EU market without understanding it routinely encounter import refusals and product detentions.
In the United States, Ayurvedic products are most commonly marketed as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). This framework does not require pre-market approval but imposes significant obligations: the product must be safe for its intended use, the label must not bear disease claims and the manufacturer must be able to demonstrate compliance with FDA Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Part 111. A foreign manufacturer supplying a US distributor or brand owner is typically expected to operate to these standards even if manufacturing takes place entirely in India.
For Ras-Rasayan products, the critical cGMP concern is identity and purity testing of raw ingredients and finished product. The FDA has in the past detained Ayurvedic products at the US border for elevated heavy-metal content, and import alerts remain active for some categories of traditional herbal and mineral products. A batch of Ras-Rasayan formulation that passes Indian Schedule T requirements may still exceed the limits that the US distributor's internal specification or the FDA's compliance threshold considers acceptable. The practical implication is that testing to US-relevant limits (which are generally expressed in parts per billion and require ICP-MS methodology) is a prerequisite for market entry, not an optional supplement to the Indian CoA.
The European Union does not have a unified framework for traditional Ayurvedic medicines that is analogous to India's AYUSH system. The Traditional Herbal Medicinal Products Directive (THMPD) provides a simplified registration route for herbal products with a 30-year history of traditional use (including 15 years in the EU), but Ras-Rasayan formulations containing mineral or metallic ingredients fall outside the scope of "herbal" products as defined by the Directive, since bhasma and Kajjali-based preparations are not plant-derived.
This means that a Ras-Rasayan product seeking the medicinal product route in the EU would need to go through full marketing authorisation, which requires clinical data that classical Ayurvedic formulations rarely have in the format European regulators expect. In practice, many Ayurvedic exporters in the EU market Ras-Rasayan products as food supplements, which removes the medicinal product pathway but subjects the product to food supplement regulations including the heavy-metal limits set by EU Regulation 2023/915 on maximum levels of contaminants in food. These limits are set for the general population and are considerably stricter than what Indian Pharmacopoeial standards permit for classical bhasma preparations.
India's Ayurvedic Pharmacopoeia sets limits for finished Ras-Rasayan products that acknowledge the presence of metals as part of the classical formulation and establish permissible ranges accordingly. The US dietary supplement framework does not set statutory finished-product limits for heavy metals in the same way, but FDA enforcement actions and the Consumer Lab and NSF standards that US retailers commonly require apply limits that can be several orders of magnitude stricter when applied to products containing bhasma.
The EU food supplement limits for mercury, lead, arsenic and cadmium are based on contaminant (not intentional ingredient) principles, which creates an inherent tension with the Ayurvedic formulation rationale. Exporters need to know at the outset whether the importing country treats bhasma metals as intentional ingredients (subject to therapeutic limits) or as contaminants (subject to background contamination limits). This classification question determines whether the product is legally marketable in that jurisdiction at all, and it should be resolved with a qualified regulatory consultant before any export production begins.
For the US market, a US distributor or brand owner importing Ras-Rasayan products will typically require: a certificate of analysis with heavy-metal results expressed in parts per billion using ICP-MS methodology, a certificate of GMP compliance (the FDA does not accept Indian Schedule T GMP certificates automatically, so a third-party audit to 21 CFR Part 111 may be needed), a complete list of ingredients with their botanical or mineralogical identity confirmed, and a label review confirming no disease claims appear.
For the EU market, documentation requirements vary by member state, but food supplement notification or registration typically requires: a product specification, safety data, the certificate of analysis from an EU-recognised or NABL-accredited laboratory, and evidence that the product does not exceed the contaminant limits of Regulation 2023/915. Some member states require notification to the national food safety authority before placing the product on the market.
A manufacturer holding a valid GMP certificate and AYUSH manufacturing licence in India provides the documentation foundation from which export compliance is built. The GMP certificate and batch manufacturing records demonstrate that the product was made under controlled conditions, which is relevant to both FDA and EU due diligence. The certificate of analysis, when issued by a NABL-accredited laboratory using ICP-MS methodology, gives the importer data that can be compared directly against the applicable limits in the destination market.
A manufacturer experienced in export supply can also advise on which formulations within the Ras-Rasayan range are likely to present fewer regulatory obstacles in specific markets, based on their mineral ingredient profile. Some formulations have simpler mineral sets that may fall within export-market limits even under strict testing regimes; others are unlikely to be marketable in markets that apply food contaminant limits to intentionally mineral-containing products. Discussing the formulation list with the manufacturer's quality team before placing any export order is time well spent.
To explore export-ready supply of Ras-Rasayan formulations, contact Raasa Ayurveda in Kanpur at +91 9415128217 or raasaayurveda@gmail.com. The team can explain the documentation available under GMP certificate D-5755/09 and AYUSH licence A-4177/2009, discuss testing options relevant to your target market, and outline the contract manufacturing and bulk supply arrangements available for export-oriented buyers.
It depends on the specific formulation and the member state. As food supplements, they are subject to EU contaminant limits that may be stricter than Indian Pharmacopoeial standards for bhasma. The medicinal product route is not straightforwardly available for mineral-containing Ayurvedic preparations. A regulatory consultant familiar with the target member state is strongly advisable before committing to export production.
Not automatically. The FDA's 21 CFR Part 111 cGMP for dietary supplements has specific requirements that may differ from Schedule T. US importers often require a third-party audit conducted to US standards, or at least a detailed facility assessment. Discuss with your US distributor what documentation they require from a foreign manufacturer before assuming the Indian GMP certificate is sufficient.
AAS (atomic absorption spectroscopy) is adequate for many domestic Indian requirements but has higher detection limits than ICP-MS (inductively coupled plasma mass spectrometry). Export markets that set heavy-metal limits in parts per billion require ICP-MS data. If your test certificate shows AAS results only, a US or EU importer may not be able to confirm compliance with their internal specification.
Formulations with simpler mineral profiles and lower inherent metal concentrations in the finished product tend to be easier to export, as they are more likely to fall within the stricter limits applied in the US and EU. Your manufacturer's quality team can advise on which formulations in the Ras-Rasayan range have finished-product metal concentrations that are most compatible with export-market testing requirements.
Raasa Ayurveda, 49/72-A, Naughara, Kanpur 208001, Uttar Pradesh, India. Telephone +91 9415128217. Email raasaayurveda@gmail.com.